Vise Technologies Inc. Acquires Shares of 15,110 Neogen Co. (NASDAQ:NEOG)

Vise Technologies Inc. bought a new position in Neogen Co. (NASDAQ:NEOG - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 15,110 shares of the company's stock, valued at approximately $280,000.

Other institutional investors have also modified their holdings of the company. Raymond James Trust N.A. boosted its stake in Neogen by 6.7% during the first quarter. Raymond James Trust N.A. now owns 6,981 shares of the company's stock valued at $215,000 after buying an additional 441 shares in the last quarter. IFP Advisors Inc bought a new stake in shares of Neogen in the 1st quarter worth approximately $57,000. Price T Rowe Associates Inc. MD lifted its stake in Neogen by 1.9% during the second quarter. Price T Rowe Associates Inc. MD now owns 40,163 shares of the company's stock valued at $968,000 after purchasing an additional 759 shares during the last quarter. Yousif Capital Management LLC grew its position in Neogen by 1.8% in the first quarter. Yousif Capital Management LLC now owns 57,421 shares of the company's stock worth $1,771,000 after buying an additional 1,018 shares during the last quarter. Finally, BNP Paribas Arbitrage SA grew its position in Neogen by 4.0% in the first quarter. BNP Paribas Arbitrage SA now owns 31,896 shares of the company's stock worth $984,000 after buying an additional 1,213 shares during the last quarter. Institutional investors and hedge funds own 93.35% of the company's stock.

Shares of Neogen stock opened at $22.77 on Tuesday. Neogen Co. has a 12 month low of $10.49 and a 12 month high of $24.09. The company has a quick ratio of 3.11, a current ratio of 4.03 and a debt-to-equity ratio of 0.28. The business has a fifty day simple moving average of $22.06 and a 200-day simple moving average of $19.43.

Neogen (NASDAQ:NEOG - Get Free Report) last posted its quarterly earnings results on Thursday, July 27th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.03 by $0.11. The business had revenue of $241.80 million during the quarter, compared to analysts' expectations of $227.72 million. Neogen had a negative net margin of 2.78% and a positive return on equity of 4.06%. The firm's quarterly revenue was up 71.4% compared to the same quarter last year. During the same period last year, the company posted $0.18 earnings per share. Equities analysts predict that Neogen Co. will post 0.58 earnings per share for the current fiscal year.

Several research firms have recently weighed in on NEOG. Wells Fargo & Company raised their price objective on Neogen from $22.00 to $28.00 and gave the stock an "overweight" rating in a research note on Monday, August 14th. StockNews.com assumed coverage on shares of Neogen in a research note on Thursday, August 17th. They set a "sell" rating for the company. Finally, Piper Sandler lifted their target price on shares of Neogen from $19.00 to $24.00 in a research report on Monday, August 7th.

Read Our Latest Research Report on NEOG

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.

Want to see what other hedge funds are holding NEOG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neogen Co. (NASDAQ:NEOG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Neogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neogen wasn't on the list.

While Neogen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.